Project Grant R01CA315249
- Federal Project Grant Award Summary Emory University received a $572,378 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) effective May 1, 2026, through April 30, 2031. The award funds fundamental research investigating the metabolic mechanisms that regulate dormancy in disseminated non-small cell lung cancer (NSCLC) subpopulations. The research employs an image-guided genomics approach to examine how collective invasion packs...
- Federal Project Grant Award Summary Emory University received a $636,358 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective June 18, 2026, with completion targeted for May 31, 2031. The award funds research aimed at reversing immune exclusion in pancreatic ductal adenocarcinoma (PDAC) through targeting of vasoactive intestinal peptide (VIP) and VIP receptor (VPAC) signaling. The research encompasses three specific...
- Federal Grant Award Summary Emory University received a $402,401 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective April 6, 2026, with completion targeted for March 31, 2028. The project addresses pancreatic ductal adenocarcinoma (PDAC) resistance to immune checkpoint inhibitors by investigating sex-specific immune mechanisms. The research will deliver scientific findings on how the vasoactive intestinal polypeptide...
- Federal Grant Award Summary Georgetown University received a $401,115 Project Grant award from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) on May 7, 2026, with a completion date of April 30, 2028. The award supports research into innovative therapeutic strategies for pancreatic ductal adenocarcinoma (PDAC), a disease with a poor prognosis and limited treatment response to current chemotherapy and immunotherapy regimens. The research...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Emory University a $156,500 Project Grant on August 1, 2025, under the Cancer Treatment Research program (CFDA 93.395) to conduct integrated multi-omics research exploring the pathophysiology of cachexia in head and neck squamous cell carcinoma (HNSCC) patients. The two-year project, concluding July 31, 2027, will investigate the systemic biological mechanisms underlying cancer cachexia through comprehensive analysis of...
- Federal Grant Award Summary Emory University received a $402,401 Project Grant award from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) effective May 6, 2026, with completion targeted for April 30, 2028. The grant supports development of an fluorine-18 (F-18) positron emission tomography (PET) imaging tracer to non-invasively measure mutated isocitrate dehydrogenase 1 (IDH1-R132H) expression in glioma tumors. This exploratory research...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $683,970 Project Grant to Columbia University's Health Sciences Division effective April 1, 2026 through March 31, 2031, under the Cancer Treatment Research program (CFDA 93.395). This research project focuses on developing and evaluating therapeutic approaches to treat pancreatic ductal adenocarcinoma (PDAC) through stromal modification and immune modulation. The research investigates the role of αvβ5 integrin in PDAC...
- Federal Project Grant Award Summary Emory University received a $158,899 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded June 20, 2025, with completion targeted for May 31, 2027. This award supports the development of an innovative Simultaneous Intensity Energy Modulation and Compensation (SIEMAC) optimization platform and integrated quality assurance (QA) system for conformal flash proton therapy treatment of central lung...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Georgia State University Research Foundation Inc. a $406,258 Project Grant on July 15, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop novel covalent anti-cancer drugs utilizing phosphorus fluoride exchange (PFEX) click chemistry. The two-year research initiative, concluding June 30, 2027, focuses on designing privileged covalent warheads with expanded target scopes to overcome limitations of...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Virginia a $161,500 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective June 1, 2026, with completion targeted for May 31, 2028. This research initiative develops innovative methodologies for classifying heterogeneous circulating tumor cells (CTCs) from pancreatic ductal adenocarcinoma (PDAC) patients by leveraging single-cell deformability as a complementary metric to traditional...
The National Cancer Institute (NCI) awarded Emory University a Project Grant of $602,170 under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) effective June 2, 2026, through May 31, 2031. This award supports the development and validation of biomimetic migrating nanoparticles designed to target tumor stroma and neural invasion in pancreatic cancer treatment. The research involves engineering hyaluronic acid nanoparticles (HANPs) conjugated with a recombinant atFMMP14 ligand to improve drug delivery penetration through dense stromal tissue and reduce therapy resistance. Preliminary findings demonstrate that atFMMP14-HANP/SN38 formulations achieved 83-97% tumor growth inhibition and significantly reduced neural invasion in patient-derived xenograft tumor models. Building on these initial results, the funded project will advance novel atFMMP14-HANPs carrying therapeutic agents targeting key neural signals and neuron-cancer interactions, including alpha-adrenergic receptor inhibitors and sensory nerve inhibitors such as propranolol and gabapentin. This dual-mechanism approach addresses both therapeutic efficacy against drug-resistant pancreatic cancer and pain management for cancer patients experiencing neuropathic pain associated with perineural invasion. The research will be conducted at Emory University's Atlanta, Georgia facility, contributing to the NCI's broader mission of improving cancer screening, early detection, and diagnostic capabilities across diverse cancer types and patient populations.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $602.2k | 6/5/26 |